eli lilly cease and desist tirzepatide As Lilly, compounders battle over weight loss drugs, patients may lose out Tirzepatide Cease-and-Desist Blitz: Eli Lilly

A study of 42,000 adults found increased rates of hypotension events after starting GLP-1s

Adults with RA, body mass index30 kg/m2, and baseline-year disease-modifying antirheumatic drug (DMARD) therapy were included

Losing weight with semaglutide can be life-changing, but some men are left with noticeable gynecomastia

PALO ALTO, Calif., September 28, 2023 (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fit uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications

This issue of the HPCs DataPoints series explores trends in GLP-1 prescriptions in Massachusetts through September 2023 and examines the use and spending impacts of these drugs in the Commonwealth.

TRT Nation Weight Loss is a specialized telehealth platform combining testosterone replacement therapy with GLP-1 medications for men seeking concurrent metabolic and hormonal optimization